EQS-News

CompuGroup Medical SE & Co. KGaA: CGM in 2022 with double-digit revenue growth – strong 2023 guidance underlines mid-term ambitions - Seite 2

In Germany, the Hospital Future Act is accelerating. At the beginning of 2022 CGM’s order intake related to this governmental initiative for the modernization and digitization of hospitals stood at EUR 25 million. Over the year this number grew to around EUR 90 million. CGM raised the revenue target relating to the Hospital Future Act to a range of EUR 90 million to EUR 110 million, a strong proof point of the high market relevance of CGM’s product portfolio.

In the Consumer & Health Management Information Systems segment, 2022 has been a year with numerous strategic milestones. After the acquisition and successful integration of INSIGHT Health and the launch of a joint product offering for pharma companies within only eight weeks, CGM prepared the entry of a new market. With the new acquisition of a 20 percent stake in New Line based in Italy, CGM underpins its ambition to become a leading pan-European health data intelligence suite.

“Despite 2022 having been a challenging year, CompuGroup Medical delivered another record performance, both in terms of revenues and operating profit. We are well on track towards our mid-term ambitions, helping our customers benefitting from digitization opportunities in the e-health sector”, said Michael Rauch, Spokesman for the Managing Directors and CFO of CompuGroup Medical. “All segments delivered a strong full year 2022 performance, which underlines the attractiveness of our e-health solutions and the customer dedication of our team. For 2023 we expect ongoing growth and over-proportionate bottom line contribution.”

Group: Revenues and adjusted EBITDA with attractive development in 2022

Group revenues increased by 10 % to a new record level of EUR 1,130 million (previous year: EUR 1,025 million). Organic revenue growth – i.e. adjusted for consolidation and currency effects – stood at 4.1 %. Adjusted for the 2021 TI connector software upgrade, organic revenue growth amounted to 6.3 %. Adjusted EBITDA reached EUR 234 million, representing a growth of 4 % year-on-year, and reflecting an adjusted EBITDA margin of 20.7 % (FY 2021: 21.9 %). Throughout the year 2022, the quality of revenues, reflected by the share of recurring revenues, has been impacted by larger one-time effects and stood solid with 65 % at the prior year level. Adjusted earnings per share (diluted) amounted to EUR 1.80 (FY 2021: EUR 1.95). With EUR 69 million, free cash flow is at the upper end of the updated full year guidance of EUR 40 million to EUR 70 million.